DK0984777T3 - Arylsubstituerede piperaziner, der er anvendelige ved behandlingen af godartet prostatisk hyperplasi - Google Patents

Arylsubstituerede piperaziner, der er anvendelige ved behandlingen af godartet prostatisk hyperplasi

Info

Publication number
DK0984777T3
DK0984777T3 DK98920950T DK98920950T DK0984777T3 DK 0984777 T3 DK0984777 T3 DK 0984777T3 DK 98920950 T DK98920950 T DK 98920950T DK 98920950 T DK98920950 T DK 98920950T DK 0984777 T3 DK0984777 T3 DK 0984777T3
Authority
DK
Denmark
Prior art keywords
aryl
treatment
benign prostatic
prostatic hyperplasia
substituted piperazines
Prior art date
Application number
DK98920950T
Other languages
Danish (da)
English (en)
Inventor
Linda Jolliffe
William Murray
Virginia Pulito
Alan Reitz
Linda Mulcahy
Frank Villani
Xiaobing Li
Cynthia Maryanoff
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Application granted granted Critical
Publication of DK0984777T3 publication Critical patent/DK0984777T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/08—Oxygen atoms
    • C07D223/10—Oxygen atoms attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
DK98920950T 1997-05-12 1998-05-08 Arylsubstituerede piperaziner, der er anvendelige ved behandlingen af godartet prostatisk hyperplasi DK0984777T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4623697P 1997-05-12 1997-05-12
PCT/US1998/009023 WO1998051298A1 (fr) 1997-05-12 1998-05-08 Piperazines a substitution aryle utiles dans le traitement de l'adenome prostatique

Publications (1)

Publication Number Publication Date
DK0984777T3 true DK0984777T3 (da) 2003-12-08

Family

ID=21942353

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98920950T DK0984777T3 (da) 1997-05-12 1998-05-08 Arylsubstituerede piperaziner, der er anvendelige ved behandlingen af godartet prostatisk hyperplasi

Country Status (27)

Country Link
US (4) US6071915A (fr)
EP (1) EP0984777B1 (fr)
JP (1) JP4189867B2 (fr)
KR (1) KR100440755B1 (fr)
CN (3) CN1515556A (fr)
AP (1) AP1349A (fr)
AR (1) AR012686A1 (fr)
AT (1) ATE250033T1 (fr)
AU (1) AU7366998A (fr)
BR (1) BR9809804A (fr)
CA (1) CA2289987C (fr)
CZ (1) CZ298217B6 (fr)
DE (1) DE69818255T2 (fr)
DK (1) DK0984777T3 (fr)
EA (1) EA001904B1 (fr)
ES (1) ES2206928T3 (fr)
HU (1) HUP0100048A3 (fr)
IL (1) IL132836A0 (fr)
MY (2) MY122095A (fr)
NO (1) NO314144B1 (fr)
NZ (1) NZ500992A (fr)
PL (1) PL192596B1 (fr)
PT (1) PT984777E (fr)
TR (1) TR199902971T2 (fr)
TW (1) TW512146B (fr)
WO (1) WO1998051298A1 (fr)
ZA (1) ZA983968B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2768055A1 (fr) * 1997-09-11 1999-03-12 Synthelabo Utilisation de derives de sulfonanilide pour obtenir un medicament destine au traitement de l'ejaculation retrograde ou de l'aspermie
TW536538B (en) 1998-02-20 2003-06-11 Ortho Mcneil Pharm Inc Phthalimido arylpiperazines useful in the treatment of benign prostatic hyperplasia
EP1346983A3 (fr) * 1998-02-20 2003-12-03 Ortho-Mcneil Pharmaceutical, Inc. Phthalimido-arylpiperazines utiles dans le traitement de l'hyperplasie prostatique bénigne en tant qu'antagonistes du récepteur alpha 1A
ZA991319B (en) * 1998-02-20 2000-11-20 Ortho Mcneil Pharm Inc Novel phthalimido arylpiperazines useful in the treatment of benign prostatic hyperplasia.
AU2001290743A1 (en) * 2000-09-14 2002-03-26 Ortho-Mcneil Pharmaceutical, Inc. Solid salt forms of n-(2-(4-(2-(1-methylethoxy)phenyl)-1-piperazinyl)ethyl)-2-oxo-1-piperidineacetamide
EP1339682A1 (fr) * 2000-11-30 2003-09-03 Ranbaxy Laboratories, Ltd. Derives de piperazine 1,4-disubstitues utiles comme bloqueurs uroselectifs des recepteurs alpha 1?-adrenergiques
WO2005118537A2 (fr) * 2004-05-31 2005-12-15 Ranbaxy Laboratories Limited Antagonistes des recepteurs adrenergiques
WO2006092710A1 (fr) * 2005-03-02 2006-09-08 Ranbaxy Laboratories Limited Metabolites de la 2-{3-[4-(2-isopropoxyphenyl)piperazin-1-yl]-propyl}-3a,4,7,7a-tetrahydro-1h-isoindole-1,3-(2h)-dione
WO2007029156A2 (fr) * 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Derives d'isoindoledione comme antagonistes de recepteurs adrenergiques
CN102391169B (zh) * 2011-10-17 2015-10-28 上海化学试剂研究所 N-(5-甲氧基-3-吲哚乙基)-4-取代苯基哌嗪-1-乙酰胺的制备方法
CN103387531A (zh) * 2012-05-10 2013-11-13 广州医学院 酰胺类芳基哌嗪衍生物及其制备方法和在抗良性前列腺增生中的应用
CN103980195A (zh) * 2014-04-28 2014-08-13 广州医科大学 酰胺类苯基哌嗪衍生物及其盐与在制备治疗良性前列腺增生症药物中的应用
WO2025034510A1 (fr) 2023-08-04 2025-02-13 University Of Rochester Antagonistes adrénergiques destinés à être utilisés dans une méthode de traitement d'un œdème cérébral ou d'une lésion cérébrale

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069336A (en) * 1976-02-25 1978-01-17 Chemisches Laboratorium Fritz-Walter Lange Gmbh & Co Kg (2-oxo-pyrrolidines)-acetic hydrazides
JPS5955878A (ja) 1982-09-24 1984-03-31 Chugai Pharmaceut Co Ltd 新規なフエニルピペラジン誘導体
WO1984004302A1 (fr) * 1983-04-27 1984-11-08 Byk Gulden Lomberg Chem Fab Acides picoliniques substitues, leurs procedes de preparation, leur utilisation et medicaments les contenant
JPS62135464A (ja) * 1985-12-10 1987-06-18 Nippon Kayaku Co Ltd フエニルピペラジン誘導体
GB8703749D0 (en) 1987-02-18 1987-03-25 Sandoz Ltd Piperazinecarboxylic acid
US5254552A (en) * 1988-05-24 1993-10-19 American Home Products Corporation Aryl-and heteroaryl piperazinyl carboxamides having central nervous system activity
SG65570A1 (en) * 1992-02-25 1999-06-22 Recordati Chem Pharm Heterobicyclic compounds
FR2692894B1 (fr) * 1992-06-24 1994-10-14 Irceba Aryl-1-(o-alcoxy-phényl-4-pipérazinyl-1)-2, 3- ou 4-alcanols, leur procédé de préparation et leur utilisation pour la préparation de médicaments.
US5403847A (en) * 1992-11-13 1995-04-04 Synaptic Pharmaceutical Corporation Use of α1C specific compounds to treat benign prostatic hyperlasia
IT1266582B1 (it) * 1993-07-30 1997-01-09 Recordati Chem Pharm Derivati (di)azacicloesanici e diazacicloeptanici
US5688795A (en) * 1994-11-08 1997-11-18 Syntex (U.S.A.) Inc. 3-(4-phenylpiperazin-1-yl)propyl-amino, thio and oxy!-pyridine, pyrimidine and benzene derivatives as α1 -adrenoceptor antagonists
US5807856A (en) * 1995-11-15 1998-09-15 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonist
EP0881235A1 (fr) * 1997-05-26 1998-12-02 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Nouveaux ylures de phosphore, leur préparation et leurs utilisations notamment en tant que bases fortes faiblement nucléophiles
ZA991315B (en) * 1998-02-20 2000-11-20 Ortho Mcneil Pharm Inc Novel substituted pyridino arylpiperazines useful in the treatment of benign prostatic hyperplasia.
TW536538B (en) * 1998-02-20 2003-06-11 Ortho Mcneil Pharm Inc Phthalimido arylpiperazines useful in the treatment of benign prostatic hyperplasia
US6063785A (en) * 1999-02-17 2000-05-16 Ortho-Mcneil Pharmaceutical Inc. Phthalimido arylpiperazines useful in the treatment of benign prostatic hyperplasia

Also Published As

Publication number Publication date
NO314144B1 (no) 2003-02-03
AP9901684A0 (en) 1999-12-31
CN1515556A (zh) 2004-07-28
CN1149081C (zh) 2004-05-12
AR012686A1 (es) 2000-11-08
CZ298217B6 (cs) 2007-07-25
PL192596B1 (pl) 2006-11-30
DE69818255D1 (de) 2003-10-23
MY122095A (en) 2006-03-31
CN1269807C (zh) 2006-08-16
BR9809804A (pt) 2000-06-27
EP0984777A1 (fr) 2000-03-15
US20030220493A1 (en) 2003-11-27
HUP0100048A2 (hu) 2001-07-30
TW512146B (en) 2002-12-01
KR100440755B1 (ko) 2004-07-21
CA2289987A1 (fr) 1998-11-19
WO1998051298A1 (fr) 1998-11-19
US6593474B1 (en) 2003-07-15
TR199902971T2 (xx) 2001-03-21
HUP0100048A3 (en) 2002-12-28
AP1349A (en) 2004-12-17
DE69818255T2 (de) 2004-12-23
CZ399799A3 (cs) 2000-04-12
EA199900928A1 (ru) 2000-08-28
CA2289987C (fr) 2006-03-14
US6890921B1 (en) 2005-05-10
PT984777E (pt) 2004-01-30
HK1024630A1 (en) 2000-10-20
MY127385A (en) 2006-11-30
PL342518A1 (en) 2001-06-18
US6071915A (en) 2000-06-06
ES2206928T3 (es) 2004-05-16
ATE250033T1 (de) 2003-10-15
EA001904B1 (ru) 2001-10-22
CN1264300A (zh) 2000-08-23
JP2002511065A (ja) 2002-04-09
JP4189867B2 (ja) 2008-12-03
IL132836A0 (en) 2001-03-19
ZA983968B (en) 1999-11-11
EP0984777B1 (fr) 2003-09-17
EP0984777A4 (fr) 2001-04-25
CN1515563A (zh) 2004-07-28
KR20010012505A (ko) 2001-02-15
NZ500992A (en) 2003-02-28
NO995518L (no) 2000-01-11
AU7366998A (en) 1998-12-08
NO995518D0 (no) 1999-11-11

Similar Documents

Publication Publication Date Title
NO993396L (no) Kinolin- og kinolinforbindelser nyttige i terapi, spesielt i behandlingen av benign prostatisk hyperplasi
DE69805767D1 (de) Hochfrequenz-heizgerät
DE69939575D1 (de) Entdeckung von Diensten in unmittelbarer Nähe
DE60023982D1 (de) System zur Behandlung von benigner Prostatahyperplasie
DE69905375D1 (de) Hochfrequenzheizapparat
DK0925069T3 (da) Anvendelse af Cetrorelix til behandling af godartet prostatahypertrofi og prostatacancer
DE69832300D1 (de) Schrank und wandteil
DE69834456D1 (de) Hochfrequenz-Oszillatorschaltung
FI974211A0 (fi) Foerfarande och anordning foer produktion av rent vatten
NO995518L (no) Arylsubstituerte piperaziner brukbare ved behandling av benign prostatisk hyperplasi
NO20002804D0 (no) Konjugater som kan anvendes ved behandling av prostatakreft
IS5373A (is) Brennari
DE69828716D1 (de) Tragbarer Mikrowellenherd
DK1055026T3 (da) Strygebord
ZA991315B (en) Novel substituted pyridino arylpiperazines useful in the treatment of benign prostatic hyperplasia.
DE69903130D1 (de) Ausklappbarer bügeltisch
ZA991319B (en) Novel phthalimido arylpiperazines useful in the treatment of benign prostatic hyperplasia.
KR970052038U (ko) 캐비닛용 잠금장치
BR9608912A (pt) Agonistas de meletonina para o tratamento de hiperplasia prostática benigna
DE69839570D1 (de) Halbleiteranordnung und dessen betriebsverfahren
GB9602903D0 (en) Conjugates useful in the treatment of benign prostatic hyperplasia
DE59804165D1 (de) Muldenmangel
NO985914L (no) Energi-ekstraktor
BR9705955A (pt) Tabuada cibernética
DK9800146U3 (da) Tastaturarbejdsplade